Longitudinal Study of Different Metastatic Patterns in the Progression of Cutaneous Melanoma

Tejera‐Vaquerizo, Antonio; Barrera-Vigo, M.V.; Fernández-Canedo, I.; Blázquez-Sánchez, Nuria; Mendiola-Fernández, M.; Fernández‐Orland, Almudena; Bosch-García, Ricardo Juan; Troya-Martín, Magdalena de; Herrera‐Ceballos, Enrique

doi:10.1016/s1578-2190(07)70508-5

Cited by 15 publications

(30 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 This second theory is supported by the fact that the presence of nodal metastasis has no bearing on time to systemic metastasis. 19,20 Our findings are more in line with the marker hypothesis as performance of SLN biopsy did not confer an MSS advantage. This concept might explain also the recent lack of advantage of the early lymphadenectomy after the presence of metastases in SLN with respect to observation provided recently by the MSLT-II 2 and DeCOG trials, 3 despite the number of metastatic lymph node at the CLND has been described as a unfavourable prognostic marker.…”

Section: Discussionsupporting

confidence: 84%

“…This theory contrasts with what is known as the marker hypothesis, which holds that metastasis occurs simultaneously via lymphatic and hematogenous routes . This second theory is supported by the fact that the presence of nodal metastasis has no bearing on time to systemic metastasis . Our findings are more in line with the marker hypothesis as performance of SLN biopsy did not confer an MSS advantage.…”

Section: Discussionsupporting

confidence: 53%

See 1 more Smart Citation

Sentinel lymph node biopsy versus observation in thick melanoma: A multicenter propensity score matching study

Boada

Tejera‐Vaquerizo²,

Ribero

et al. 2017

Intl Journal of Cancer

View full text Add to dashboard Cite

The clinical value of sentinel lymph node (SLN) biopsy in thick melanoma patients (Breslow >4 mm) has not been sufficiently studied. The aim of the study is to evaluate whether SLN biopsy increases survival in patients with thick cutaneous melanoma, and, as a secondary objective, to investigate correlations between survival and lymph node status. We included 1,211 consecutive patients with thick melanomas (>4 mm) registered in the participating hospitals' melanoma databases between 1997 and 2015. Median follow-up was 40 months. Of these patients, 752 were matched into pairs by propensity scores based on sex, age, tumor location, histologic features of melanoma, year of diagnosis, hospital and adjuvant interferon therapy. The SLN biopsy vs. observation was associated with better DFS [adjusted hazard ratio (AHR), 0.74; 95% confidence interval (CI) 0.61-0.90); p = 0.002] and OS (AHR, 0.75; 95% CI, 0.60-0.94; p = 0.013) but not MSS (AHR, 0.84; 95% CI, 0.65-1.08; p = 0.165). SLN-negative patients had better 5- and 10-year MSS compared with SLN-positive patients (65.4 vs. 51.9% and 48.3 vs. 38.8%; p = 0.01, respectively). As a conclusion, SLN biopsy was associated with better DFS but not MSS in thick melanoma patients after adjustment for classic prognostic factors. SLN biopsy is useful for stratifying these patients into different prognostic groups.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionsupporting

confidence: 53%

Sentinel lymph node biopsy versus observation in thick melanoma: A multicenter propensity score matching study

Boada

Tejera‐Vaquerizo²,

Ribero

et al. 2017

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…To date, only a few studies have reported metastasizing characteristics of melanoma in particular [9][10][11][12]. Genetic aberrations, such as BRAF and KIT mutations, that might have an impact on tumor biology and thus support metastasis, have only recently been analysed in the context of organ-specific metastasis [13].…”

mentioning

confidence: 99%

Clinical implications of distinct metastasizing preferences of different melanoma subtypes

Schoenewolf

Belloni

Simcock

et al. 2014

European Journal of Dermatology

View full text Add to dashboard Cite

Background: The incidence and mortality of malignant melanoma have been rising during the past decades, the latter being due to the high invasion capacity and the metastatic potential of melanoma cells to distant organs. Objective: We investigated the distribution pattern of melanoma metastases taking into account different clinicopathological subtypes of melanoma. Methods: We studied 310 stage IV (AJCC 2009) melanoma patients retrospectively with regard to potential correlations between frequency and occurrence of metastasis and the genetic background and pathological/clinical melanoma subtypes. For all patients, the time to distant metastasis (TTDM) and the distribution patterns of metastases were analyzed and correlated to the median survival time. Results: Superficially Spreading (SSM) and Nodular melanomas (NMM) spread to the brain more frequently than Acrolentiginous (ALM) and Mucosal (MM) melanomas (p = 0.0012). The preference to affect the skeleton was significantly higher for ALM and MM in comparison to SSM and NMM (p = 0.0049). Lentigo maligna (LMM) tumors showed a significantly lower metastatic spread to distant lymph nodes (p = 0.0159). BRAF mutant versus wildtype tumors showed no significant differences concerning localization of metastasis but patients with BRAF mutant tumors were significantly younger at primary diagnosis and had a significantly shorter stage IV survival (p = 0.0106). Conclusion: This study shows a clear distinction of melanoma subtypes with regard to metastasizing preferences. Further knowledge about melanoma subtype specific characteristics, including molecular markers predictive of homing preferences, may help to understand and manage this heterogeneous disease in terms of prognosis and follow-up procedures.

show abstract

“…Satellite and in‐transit metastasis usually precedes regional lymph node metastases, while development of distant metastasis appears to be an independent event in metastatic spread 3,7 . However, few studies have paid attention to prognostic factors of melanoma patients after first recurrence 3,4,7–12 . Progression is mainly related to the site of recurrence and the tumour burden (number of metastases and involved organs).…”

Section: Introductionmentioning

confidence: 99%

“…Progression is mainly related to the site of recurrence and the tumour burden (number of metastases and involved organs). Besides, clinical and pathologic characteristics of the primary lesion (thickness, location and ulceration), patient age and gender keep their prognostic value in patients with recurrence 3,7–11 . Whether the disease‐free interval prior to recurrence is a prognostic factor is controversial 4,10,13 .…”

Section: Introductionmentioning

confidence: 99%

Mitotic rate and subcutaneous involvement are prognostic factors for survival after recurrence in patients with only locoregional skin metastasis as the first site of recurrence from cutaneous melanoma

Messeguer

Agustí-Mejias

Traves

et al. 2012

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Longitudinal Study of Different Metastatic Patterns in the Progression of Cutaneous Melanoma

Cited by 15 publications

References 22 publications

Sentinel lymph node biopsy versus observation in thick melanoma: A multicenter propensity score matching study

Sentinel lymph node biopsy versus observation in thick melanoma: A multicenter propensity score matching study

Clinical implications of distinct metastasizing preferences of different melanoma subtypes

Mitotic rate and subcutaneous involvement are prognostic factors for survival after recurrence in patients with only locoregional skin metastasis as the first site of recurrence from cutaneous melanoma

Contact Info

Product

Resources

About